Table 3. Univariate and multivariate analyses of predictors of overall survival using the Cox proportional hazards regression model.
| Variables | Univariable | Multivariable | |||
|---|---|---|---|---|---|
| HR (95% CI) | P value | HR (95% CI) | P value | ||
| Age | 0.99 (0.98–1.00) | 0.071 | 1.00 (0.96–1.03) | 0.830 | |
| Sex | |||||
| Female | 1 | 1 | |||
| Male | 0.81 (0.64–1.03) | 0.081 | 1.50 (0.69–3.25) | 0.303 | |
| BMI | 0.93 (0.90–0.97) | <0.001 | 1.01 (0.92–1.11) | 0.817 | |
| ECOG | 1.68 (1.49–1.90) | <0.001 | 1.48 (1.06–2.04) | 0.019 | |
| Stage | |||||
| III | 1 | 1 | |||
| IV | 0.42 (0.10–1.69) | 0.222 | NA | ||
| Line of chemotherapy | |||||
| 1 | 1 | 1 | |||
| 2 | 1.93 (1.31–2.86) | 0.001 | 2.38 (0.78–7.24) | 0.127 | |
| ≥3 | 2.71 (1.83–4.01) | <0.001 | 3.19 (1.04–9.82) | 0.043 | |
| Baseline NLR levels | |||||
| Physiological | 1 | 1 | |||
| Aberrant | 2.73 (2.20–3.40) | <0.001 | 1.84 (0.92–3.68) | 0.084 | |
| Early treatment period NLR levels | |||||
| Physiological | 1 | 1 | |||
| Aberrant | 4.69 (3.53–6.23) | <0.001 | 1.30 (0.61–2.80) | 0.498 | |
| Baseline CRP levels | |||||
| Physiological | 1 | 1 | |||
| Aberrant | 2.16 (1.67–2.79) | <0.001 | 1.58 (0.84–2.94) | 0.153 | |
| Early treatment period CRP levels | |||||
| Physiological | 1 | 1 | |||
| Aberrant | 6.64 (4.40–10.02) | <0.001 | 3.88 (1.55–9.72) | 0.004 | |
| Baseline LDH levels | |||||
| Physiological | 1 | 1 | |||
| Aberrant | 0.80 (0.54–1.18) | 0.257 | 0.74 (0.41–1.37) | 0.341 | |
| Early treatment period LDH levels | |||||
| Physiological | 1 | 1 | |||
| Aberrant | 4.72 (3.49–6.38) | <0.001 | 4.04 (2.01–8.12) | <0.001 | |
HR, hazard ratio; CI, confidence interval; SD, standard deviation; BMI, body mass index; ECOG, European Cooperative Oncology Group; NLR, neutrophil-lymphocyte ratio; CRP, C-reactive protein; LDH, lactate dehydrogenase.